TRAIL and cancer therapy

Cancer Letters

Volumn 263, Issue 1, 2008, Pages 14-25

  Kruyt, Frank A E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Cancer; Kinases; Therapy; TRAIL

Indexed keywords

1 [5 HYDROXY 2 (2 THIENYL) 4 QUINAZOLINYLAMINO] 3 METHYL 2,5 PYRROLEDIONE; BORTEZOMIB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GEFITINIB; GOSSYPOL; HISTONE DEACETYLASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; LEXATUMUMAB; MAPATUMUMAB; PROTEIN BCL 2; SORAFENIB; TOPOTECAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; SURVIVAL;

INTRACISTERNAL A-PARTICLES;

EID: 41049112098     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.02.003     Document Type: Review

References (85)

1. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 6 (1995) 673-682
2. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., and Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271 (1996) 12687-12690
3. Mariani S.M., and Krammer P.H. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur. J. Immonol. 28 (1998) 973-982
4. LeBlanc H.N., and Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10 (2003) 66-75
5. Kimberley F.C., and Screaton G.R. Following a TRAIL: update on a ligand and its five receptors. Cell Res. 14 (2004) 359-372
6. Degli-Esposti M.A., Smolak P.J., Walczak H., Waugh J., Huang C.P., DuBose R.F., et al. a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186 (1997) 1165-1170
7. Degli-Esposti M.A., Dougall W.C., Smolak P.J., Waugh J.Y., Smith C.A., and Goodwin R.G. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7 (1997) 813-820
8. MacFarlane M., Inoue S., Kohlhaas S.L., Majid A., Harper N., Kennedy D.B.J., et al. Chronic lymphocytic leukemia cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ. 12 (2005) 773-782
9. Park S.M., Schickel R., and Peter M.E. Nonapoptotic functions of FADD-binding death receptors and their signaling molecules. Curr. Opion Cell Biol. 17 (2005) 1-7
10. Cretney E., Takeda K., Yagita H., Glaccum M., Peschon J.J., and Smyth M.J. Increased susceptibility to tumor initiation and metastasis in TNF-apoptosis-inducing ligand-deficient mice. J. Immunol. 168 (2002) 1356-1361
11. Zerafa N., Westwood J.A., Creney E., Mitchell S., Waring P., Iezzi M., and Smyth M.J. Cutting edge: TRAIL deficiency accelerates hematological malignancies. J. Immunol. 175 (2005) 5586-5590
12. Zauli G., and Secchiero P. The role of TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev. 17 (2006) 245-257
13. Danial N.N., and Korsmeyer S.J. Cell death: critical control points. Cell 116 (2004) 205-219
14. Jin Z., and El-Deiry W.S. Overview of cell death signaling pathways. Cancer Biol. Ther. 4 (2005) 139-163
15. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17 (1998) 1675-1687
16. Ozoren N., and El-Deiry W.S. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia. 4 (2002) 551-557
17. Aggarwal B.B. Signaling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3 (2003) 745-756
18. Varfolomeev E., Maecker H., Sharp D., Lawrence D., Renz M., Vucic D., and Ashkenazi A. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J. Biol. Chem. 280 (2005) 40599-40608
19. Meng III R.D., McDonald E.R., Sheikh M.S., Fornace Jr. A.J., and El-Deiry W.S. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol. Ther. 1 (2000) 130-144
20. Werneburg N.W., Guicciardi M.E., Bronk S.F., Kaufmann S.H., and Gores G.J. Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins. J. Biol. Chem. 282 39 (2007) 28960-28970
21. Marsters S.A., Sheridan J.P., Pitti R.M., Huang A., Skubatch M., Baldwin D., et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7 (1997) 1003-1006
22. Clancy L., Mruk K., Archer K., Woelfel M., Mongkolsapaya J., Screaton G., et al. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc. Natl. Acad. Sci. USA 102 (2005) 18099-18104
23. Truneh A., Sharma S., Silverman C., Khandekar S., Reddy M.P., Deen K.C., et al. J. Biol. Chem. 275 (2000) 23319-23325
24. Wagner K.W., Punnoose E.A., Januario T., Lawrence D.A., Pitti R.M., Lancaster K., et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 13 (2007) 1070-1077
25. Xiao C., Yang B.F., Asadi N., Beguinot F., and Hao C. Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J. Biol. Chem. 277 (2002) 25020-25025
26. Song J.H., Tse M.C., Bellail A., Phuphanich S., Khuri F., Kneteman N.M., and Hao C. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res. 67 (2007) 6946-6955
27. LeBlanc H., Lawrence D., Varfolomeev E., Totpal K., Morlan J., Schow P., et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat. Med. 8 (2002) 274-281
28. Fulda S., Meyer E., and Debatin K.M. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21 (2002) 2283-2294
29. Rudner J., Jendrossek V., Lauber K., Daniel P.T., Wesselborg S., and Belka C. Type I and type II reactions in TRAIL-induced apoptosis - results from dose-response studies. Oncogene 24 (2005) 130-140
30. Taniai M., Grambihler A., Higuchi H., Werneburg N., Bronk S.F., Farrugia D.J., et al. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. 64 (2004) 3517-3524
31. Clohessy J.G., Zhuang J., de Boer J., Gil-Gómez G., and Brady H.J. Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. J. Biol. Chem. 281 (2006) 5750-5759
32. Ricci M.S., Jin Z., Dews M., Yu D., Thomas-Tikhonenko A., Dicker D.T., and El-Deiry W.S. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol. Cell. Biol. 24 (2004) 8541-8555
33. Wang Y., Engels I.H., Knee D.A., Nasoff M., Deveraux Q.L., and Quon K.C. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell. 5 (2004) 501-512
34. Ricci M.S., Kim S.H., Ogi K., Plastaras J.P., Ling J., Wang W., et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell. 12 (2007) 66-80
35. Pan G., Ni J., Wei Y.F., Yu G., Gentz R., and Dixit V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277 (1997) 815-818
36. Nesterov A., Nikrad M., Johnson T., and Kraft A.S. Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 64 (2004) 3922-3927
37. Walczak H., Miller R.E., Ariail K., Gliniak K.B., Griffith T.S., Kubin M., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5 (1999) 157-163
38. Hymowitz S.G., O'Connell M.P., Ultsch M., Hurst A., Totpal K., Ashkenazi A., de Vos A.M., and Kelley R.F. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 39 (2000) 633-640
39. Koschny R., Walczak H., and Ganten T.M. The promise of TRAIL-potential and risks of a novel anticancer therapy. J. Mol. Med. 85 (2007) 923-935
40. Pukac L., Kanakaraj P., Humphreys R., Alderson R., Bloom M., Sung C., et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br. J. Cancer 92 (2005) 1430-1441
41. Zeng Y., Wu X.X., Fiscella M., Shimada O., Humphreys R., Albert V., and Kakehi Y. Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo. Int. J. Oncol. 28 (2006) 421-430
42. Georgakis G.V., Li Y., Humphreys R., Andreeff M., O'Brien S., Younes M., Carbone A., Albert V., and Younes A. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br. J. Haematol. 130 (2005) 501-510
43. Marini P., Denzinger S., Schiller D., Kauder S., Welz S., Humphreys R., et al. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 25 (2006) 5145-5154
44. Duiker E.W., Mom C.H., de Jong S., Willemse P.H., Gietema J.A., van der Zee A.G., and de Vries E.G. The clinical trail of TRAIL. Eur. J. Cancer. 42 (2006) 2233-2240
45. Takeda K., Yamaguchi N., Akiba H., Kojima Y., Hayakawa Y., Tanner J.E., Sayers T.J., et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J. Exp. Med. 199 (2004) 437-448
46. Kelley R.F., Totpal K., Lindstrom S.H., Mathieu M., Billeci K., Deforge L., Pai R., Hymowitz S.G., and Ashkenazi A. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J. Biol. Chem. 280 (2005) 2205-2212
47. MacFarlane M., Kohlhaas S.L., Sutcliffe M.J., Dyer M.J., and Cohen G.M. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res. 65 (2005) 11265-11270
48. van der Sloot A.M., Tur V., Szegezdi E., Mullally M.M., Cool R.H., Samali A., Serrano L., and Quax W.J. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc. Natl. Acad. Sci. USA 103 (2006) 8634-8639
49. Abou El Hassan M.A., Mastenbroek D.C., Gerritsen W.R., Giaccone G., and Kruyt F.A. Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL. Br. J. Cancer 91 (2004) 171-177
50. Zhang X., Cheung R.M., Komaki R., Fang B., and Chang J.Y. Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer. Clin. Cancer Res. 11 (2005) 6657-6668
51. Shin M.S., Kim H.S., Lee S.H., Park W.S., Kim S.Y., Park J.Y., et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res. 61 (2001) 4942-4946
52. Lee S.H., Shin M.S., Kim H.S., Lee H.K., Park W.S., Kim S.Y., et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res. 59 (1999) 5683-5686
53. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104 (1999) 155-162
54. Jin H., Yang R., Fong S., Totpal K., Lawrence D., Zheng Z., et al. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res 64 (2004) 4900-4905
55. Chinnaiyan A.M., Prasad U., Shankar S., Hamstra D.A., Shanaiah M., Chenevert T.L., Ross B.D., and Rehemtulla A. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl. Acad. Sci. USA 97 (2000) 1754-1759
56. Petak I., and Houghton J.A. Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Pathol. Oncol. Res. 7 (2001) 95-106
57. Van Geelen C.M., de Vries E.G., and de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug. Resist. Updat. 7 (2004) 345-358
58. Meurette O., Fontaine A., Rebillard A., Le Moigne G., Lamy T., Lagadic-Gossmann D., and Dimanche-Boitrel M.T. Cytotoxicity of TRAIL/anticancer drug combinations in human normal cells. Ann. NY Acad. Sci. 1090 (2006) 209-216
59. Jin X., Wu X.X., Abdel-Muneem Nouh M.A., and Kakehi Y. Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin. J. Urol. 177 (2007) 1894-1899
60. Deeb D., Xu Y.X., Jiang H., Gao X., Janakiraman N., Chapman R.A., and Gautam S.C. Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol. Cancer Ther. 2 (2003) 95-103
61. Fulda S., and Debatin K.M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res. 64 (2004) 337-346
62. Delmas D., Rébé C., Micheau O., Athias A., Gambert P., Grazide S., Laurent G., Latruffe N., and Solary E. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene 23 (2004) 8979-8986
63. Shankar S., Siddiqui I., and Srivastava R.K. Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. Mol. Cell Biochem. 304 (2007) 273-285
64. Wang J.-L., Liu D., Zhang Z.-J., Shan S., Han X., Srinivasula S.M., et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sci. USA 97 (2000) 7124-7129
65. Sinicrope F.A., Penington R.C., and Tang X.M. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells. Clin. Cancer Res. 10 (2004) 8284-8292
66. Yeow W.S., Baras A., Chua A., Nguyen D.M., Sehgal S.S., Schrump D.S., and Nguyen D.M. Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J. Thorac. Cardiovasc. Surg. 132 (2006) 1356-1362
67. Fulda S., Wick W., Weller M., and Debatin K.M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 8 (2002) 808-815
68. Li L., Thomas R.M., Suzuki H., De Brabander J.K., Wang X., and Harran P.G. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 305 (2004) 1471-1474
69. Voortman J., Resende T.P., Abou El Hassan M.A., Giaccone G., and Kruyt F.A. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol. Cancer Ther. 6 (2007) 2103-2112
70. Liu X., Yue P., Chen S., Hu L., Lonial S., Khuri F.R., and Sun S.Y. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res. 67 (2007) 4981-4988
71. Khanbolooki S., Nawrocki S.T., Arumugam T., Andtbacka R., Pino M.S., Kurzrock R., et al. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol. Cancer Ther. 5 (2006) 2251-2260
72. Romagnoli M., Desplanques G., Maiga S., Legouill S., Dreano M., Bataille R., and Barille-Nion S. Canonical nuclear factor {kappa}B pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL. Clin. Cancer Res. 13 (2007) 6010-6018
73. Meng X.W., Lee S.D., Dai H., Loegering D., Yu C., Flatten K., et al. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J. Biol. Chem. 282 (2007) 29831-29846
74. Rosato R.R., Almenara J.A., Coe S., and Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res. 67 (2007) 9490-9500
75. Teraishi F., Kagawa S., Watanabe T., Tango Y., Kawashima T., Umeoka T., et al. Z1839 (Gefitinib,'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. FEBS Lett. 549 (2005) 4069-4075
76. Shrader M., Pino M.S., Lashinger L., Bar-Eli M., Adam L., Dinney C.P., and McConkey D.J. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res. 67 (2007) 1430-1435
77. Ruefli A.A., Ausserlechner M.J., Bernhard D., Sutton V.R., Tainton K.M., Kofler R., Smyth M.J., and Johnstone R.W. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl. Acad. Sci. USA 98 (2001) 10833-10838
78. Insinga A., Monestiroli S., Ronzoni S., Gelmetti V., Marches F., Viale A., et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. 11 (2005) 71-76
79. Erratum in Nat. Med. 11 (2005) 233
80. Rosato R.R., Almenara J.A., Dai Y., and Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. 2 (2003) 273-1284
81. Zopf S., Neureiter D., Bouralexis S., Abt T., Glaser K.B., Okamoto K., et al. Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo. Int. J. Oncol. 31 (2007) 391-1402
82. Herbst R.S., Mendelson D.S., Ebbinghaus S., Gordon M.S., O'Dwyer P., Lieberman G., et al. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. J. Clin. Oncol. ASCO Ann. Meeting Proc. 24 (2006) 3013
83. Tolcher A.W., Mita M., Meropol N.J., von Mehren M., Patnaik A., Padavic K., et al. Phase 1 pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor/related apoptosis-inducing ligand receptor-1. J. Clin. Oncol. 25 (2007) 1390-1396
84. Younes A., Vose J., Zelenetz A.D., et al. Results of a phase 2 trial of HGS-ETR 1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) in subjects with relapsed/refractory non-Hodgkin's Lymphoma (NHL). Blood 106 (2005) 146-7A
85. Plummer R., Attard G., Pacey S., Li L., Razak A., Perrett R., et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin. Cancer Res. 13 (2007) 6187-6194